Introduction Acromegaly is a chronic systemic rare disease most commonly caused by a somatotroph pituitary adenoma with autonomous overproduction of growth hormone (GH) and a consequent increase in insulin-like growth factor type I (IGF
Novel therapies for acromegaly
Bernardo Maia, Leandro Kasuki, and Mônica R Gadelha
Prevalence of diabetes mellitus in patients with acromegaly
A V Dreval, I V Trigolosova, I V Misnikova, Y A Kovalyova, R S Tishenina, I A Barsukov, A V Vinogradova, and B H R Wolffenbuttel
Introduction Disturbances of glucose metabolism are frequently observed in patients with acromegaly. In one of the first papers to be published on this topic, abnormal glucose tolerance was found in over 60% of patients with acromegaly (1) . The
Acromegaly and the information gap: patient perceptions of the journey from primary to tertiary care
Hei Yi Vivian Pak, Andrew Lansdown, Peter Taylor, Dafydd Aled Rees, John Stephen Davies, and Caroline Hayhurst
Introduction Acromegaly, usually due to a benign pituitary adenoma, is a rare condition that has profound effects on all aspects of the body ( 1 ). Besides causing soft-tissue growth, excess growth hormone is associated with co
Persistent inflammation and endothelial dysfunction in patients with treated acromegaly
T L C Wolters, C D C C van der Heijden, N van Leeuwen, B T P Hijmans-Kersten, M G Netea, J W A Smit, D H J Thijssen, A R M M Hermus, N P Riksen, and R T Netea-Maier
Introduction Acromegaly is caused by overproduction of growth hormone (GH), in most cases by a pituitary adenoma. GH in turn induces production of insulin-like growth factor 1 (IGF1) ( 1 ). Both GH and IGF1 have numerous metabolic and trophic
Risk factors and management of pasireotide-associated hyperglycemia in acromegaly
Mônica R Gadelha, Feng Gu, Marcello D Bronstein, Thierry C Brue, Maria Fleseriu, Ilan Shimon, Aart J van der Lely, Shoba Ravichandran, Albert Kandra, Alberto M Pedroncelli, and Annamaria A L Colao
Introduction Acromegaly is a chronic endocrine disorder typically caused by a benign tumor of the pituitary gland ( 1 ), which hypersecretes growth hormone (GH) with subsequent secretion of insulin-like growth factor I (IGF-I). Long
Attitudes and preferences in patients with acromegaly on long-term treatment with somatostatin analogues
Cecilia Follin and Sven Karlsson
Introduction Acromegaly is a rare chronic condition caused by excess growth hormone (GH) secretion – usually from a pituitary tumour – and it has an incidence rate of only 3.3 cases per million people. The mean age at diagnosis is 40 years
Short-term efficacy of recombinant human GH therapy in cured acromegaly patients with GH deficiency: a single-center experience
Pinaki Dutta, Bhuvanesh Mahendran, K Shrinivas Reddy, Jasmina Ahluwalia, Kim Vaiphei, Rakesh K Kochhar, Prakamya Gupta, Anand Srinivasan, Mahesh Prakash, Kanchan Kumar Mukherjee, Viral N Shah, Girish Parthan, and Anil Bhansali
Introduction Acromegaly is most commonly caused by a growth hormone (GH)-producing pituitary tumor and is potentially life-threatening if untreated. Early diagnosis and treatment of acromegaly result in increased longevity and better quality of life
In active acromegaly, IGF1 bioactivity is related to soluble Klotho levels and quality of life
A J Varewijck, A J van der Lely, S J C M M Neggers, S W J Lamberts, L J Hofland, and J A M J L Janssen
Introduction Acromegaly is characterized by excess secretion of growth hormone (GH) causing multisystem-associated morbidities and increased mortality. GH is considered as the main regulator of circulating total insulin-like growth factor 1 (IGF1
Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR
Peter Wolf, Alexandre Dormoy, Luigi Maione, Sylvie Salenave, Jacques Young, Peter Kamenický, and Philippe Chanson
Introduction Acromegaly results in a clinical syndrome following increased serum concentrations of growth hormone (GH) and insulin-like growth factor-1 (IGF-1). If not adequately treated, GH excess is associated with increased morbidity and
Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly
Nelma Veronica Marques, Luiz Eduardo Armondi Wildemberg, and Monica R Gadelha
Introduction Pasireotide long-acting release is a multireceptor-targeted somatostatin receptor ligand (SRL) approved to treat adult patients with acromegaly ( 1 ). In patients, this second-generation SRL has been shown to be effective in
